Yogesh Jethava, MD
University of Iowa, Holden Cancer Center 
Interview Date: April 18, 2019

Most myeloma patients are familiar with how the chemotherapy melphalan is used during stem cell transplant. It is typically used in high doses and remains the single most effective drug to kill myeloma, but has significant side effects. Dr. Yogesh Jethava of the University of Iowa joins us to share how his open clinical trial for relapsed or refractory myeloma patients (those who have failed proteasome inhibitors, immunomodulators or daratumumab) can use low doses of melphalan combined with high dose IV Vitamin C. Dr. Jethava shares two more upcoming studies (smoldering myeloma and older patients who are currently transplant ineligible) that will open soon. Learn more about this fascinating use of existing drugs in combination. 

Thanks to our episode sponsor